|
Geographic Atrophy: Rapid Response from ARVO
Geographic atrophy (GA) is a pathological deterioration of the retina seen in the late stages of age-related macular degeneration (AMD). It affects 20% of people with AMD, and its prevalence increases exponentially with age. Until recently, there were no treatment options for GA, but investigation into the complement system and its role in the pathogenesis of GA has led to targeted therapies that have revolutionized the treatment paradigm. Because of the recent approval of one of these therapi... |
|
Case Challenges in nAMD and DME Management: Achieving Durable Response
The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with uni... |
|
Meeting Milestones in nAMD and DME Management: What's New?
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized treatment paradigms for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, these agents are associated with a high treatment burden because of the injection frequency, and a substantial number of patients do not adhere to their treatment schedules, resulting in suboptimal response to therapy. To address these issues, new dosage regimens and surgical drug delivery approaches hav... |
|
32nd Annual Primary Care Conference, Session 1
Continuing Education Company has been organizing its Primary Care Conference Series for over 31 years. The Primary Care Conference is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us this June or July when we hold the 32nd Annual Primary Care Conference. This conference will be repeated in two sessions for convenience in scheduling. Sessions I and II will be held at the Kiawah Is... |
|
Ace the Case: An 84-Year-Old Man With Neovascular Age-Related Macular Degeneration Receiving Bilateral Every 8-Week Anti-Vascular Endothelial Growth Factor Injections
In this clinical case review, Dr. Emmanuel Chang explores options to extend treatment intervals in a patient with stable nAMD who is receiving anti-VEGF therapy every 8 weeks. |
|
Ace the Case: A 65-Year-Old Woman With Chronic Diabetic Macular Edema in Both Eyes
In this clinical case review, Dr. Sara Haug explores considerations for the management of a patient with DME who is receiving monthly anti-VEGF therapy without attaining disease control. |
|
Ace the Case: A 76-Year-Old Male With Active Neovascular Age-Related Macular Degeneration
In this clinical case review, Dr. Arshad Khanani explores options for switching treatment in a patient with nAMD who has become nonresponsive to anti-vascular endothelial growth factor (VEGF) therapy. |
|
32nd Annual Primary Care Conference, Session 2
Continuing Education Company has been organizing its Primary Care Conference Series for over 31 years. The Primary Care Conference is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. Join us this June or July when we hold the 32nd Annual Primary Care Conference. This conference will be repeated in two sessions for convenience in scheduling. Sessions I and II will be held at the Kiawah Is... |
|
The Art of Ophthalmology Medicine: Individualizing Therapy in Neovascular Age-Related Macular Degeneration in an Era of Expanded Treatment Options; AMD Virtual Pathways Activity
Target Audience
This initiative is designed to meet the educational needs of retina/ophthalmology, optometry, managed care, primary care/internal medicine, diabetes education, and cardiology/endocrinology sub-specialties.
Program Overview
This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD) based on patient-, disease-, and treatment-related factors. Listen to a retina expert talk about some of the technological ... |
|
Recognition and Referral: Best Practices for Managing Patients with GA
Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interactive, virtual symposia are designed to educate eye care providers on the importance of diagnosis and ... |
|
The Art of Ophthalmology Medicine: Individualizing Therapy in Neovascular Age Related Macular Degeneration in an Era of Expanded Treatment Options; nAMD Day in the Life
Target Audience
This initiative is designed to meet the educational needs of retina/ophthalmology, optometry, managed care, primary care/internal medicine, diabetes education, and cardiology/endocrinology sub-specialties.
Program Overview
This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD). Providers will learn about the safety, efficacy, and durability of established and emerging nAMD therapies, as well as tec... |